20/20 Biolabs, Inc. (AIDX) intrinsic value & 10-year financials
20/20 Biolabs, Inc. (AIDX) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 3 fiscal years revenue grew 16.7% a year to $2.0M, with an average return on invested capital of 1617.7%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.26
- Market cap
- $1.3M
- Revenue (FY2025)
- $2.0M
- Revenue growth (3-yr CAGR)
- 16.7%
- ROIC (10-yr avg)
- 1617.7%
- Free cash flow (FY2025)
- —
AIDX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $2.0M | -$3.7M | -$0.76 | — | -162.9% | 4639.7% |
| FY2024 | $1.8M | -$5.6M | -$1.16 | — | -324.0% | -1404.3% |
| FY2023 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
20/20 Biolabs, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
20/20 Biolabs, Inc. has earned high returns on invested capital, averaging 16.2% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
20/20 Biolabs, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, 20/20 Biolabs, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-25.24 per share.